Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 53, Issue 69, 2006, Pages 409-414

  Peng, Baogang ^a   Liang, Lijian ^a   Chen, Zubing ^a   He, Qiang ^a   Kuang, Ming ^a   Zhou, Fan ^a   Mingde, ^a   Lu, ^a   Huang, Jiefu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Immmunotherapy; Recurrence; Vaccine

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ADULT; ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; INOCULATION; LIVER CELL CARCINOMA; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; TIME FACTORS;

EID: 33745449823     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Peto J: Cancer epidemiology in the last century and the next decades. Nature 2001; 411:390-395.
2. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH: Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91:1479-1486.
3. Poon RT, Fan ST, Lo CM, Liu CL, Wong J: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235:373-382.
4. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
5. Lee WC, Jeng LB, Chen MF: Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg 2002; 89:311-316.
6. Berd D, Maquire HCJ, McCue P, Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-1867.
7. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990; 32:62-66.
8. Soiffer R, Lynch T, Mihin M, Jung K, Rhuda C, Schniollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singe S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Bems A, Clift S, Cohen LK, Mulligan RC, Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95:13141-13146.
9. Johbston D, Bystryn JC: Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. J Natl Cancer Inst 1991; 83:1240-1245.
10. Huang L, Li S: Liposomal gene delivery: A complex package. Nature Biotechnol 1997; 15:620-621.
11. Protti MP, Bellone M: Immunotherapy: natural versus synthetic peptides. Immunol Today 1998; 19:98-101.
12. Mayordomo J, Zorina T, Storkus WJ, Zitvoge L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1:1297-1302.
13. Pardoll DM: Cancer vaccines. Nature Med vaccine supplement 1998; 4:525-531.
14. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997; 3:558-561.
15. Lin SQ, Saijo K, Todoroki T, Ohno T: Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Med 1995; 1:267-271.
16. Liu SQ, Shiraiwa H, Kawai K, Hayashi H, Akaza H, Kim BS, Oki A, Nishida M, Kubo T, Hashizaki K, Saijo K, Ohno T: Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nature Med 1996; 2:1283-1285.
17. Kim C, Matsumura M, Saijo K, Ohno T: In vitro induction of HLA-A2404-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47:90-96.
18. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N: Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-1368.
19. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nature Med 1999; 5:1249-1255.
20. Volgmann T, Klein-Struckmeier A, Mohr H: A fluorescence-based assay for quantiation of lymphokine-activated killer cell activity. J Immunol Methods 1989; 119:45-51.
21. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC: Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nature Med 1997; 3:451-455.
22. Falo LDJ, Kovacsovics-Bankowski M, Thompson K, Rock KL: Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med 1995; 1:649-653.
23. Harding CV, Song R: Phagocytic processing of exogenous particulate antigen by macrophages for presentation by class MHC I molecules. J Immunol 1994; 153:4925-4933.
24. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993; 90:4942-4946.
25. Rock KL, Clark K: Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen MHC class I presentation pathway. J Immunol 1996; 156:3721-3726.
26. Nair S, Zhou F, Reddy R, Huang L, Rouse BT: Soluble protein delivered to dendritic cells via PH-sensitive liposomes induce primary cytotoxic T lymphocytes responses in vitro. J Exp Med 1992; 175:609-612.
27. De Bruijn M, Jackson MR, Peterson P: Phagocyte-induced antigen-specific activation of unprimed CD8+T cells in vitro. Eur J Immunol 1995; 25:1274-1285.
28. De Bruijn M, Peterson PA, Jackson MR: Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. J Immunol 1996; 156:2686-2692.